Sep 12 2012

george

Validating High POC INR Results

Our April 24, 2012 post (and Quick Question), POC: When to Validate a High INR has attracted a provocative comment from Alan Neal of New Zealand. I’ve added this link so the comment does not get buried and to attract additional discussion from our participants.

read more

Comments (0)

Anticoagulant Therapy

Sep 12 2012

george

Validating High POC INR Results

Our April 24, 2012 post (and Quick Question), POC: When to Validate a High INR has attracted a provocative comment from Alan Neal of New Zealand. I’ve added this link so the comment does not get buried and to attract additional discussion from our participants.

read more

Comments (0)

Anticoagulant Therapy

Sep 12 2012

george

Hybrid Curve Controls for Anti-Xa Heparin Assay

This is from frequent contributor Crystal Azevedo, Eastern Maine Healthcare Systems. Hi George, Look forward to seeing you next month in Portland, Maine! I am setting up a hybrid curve for heparin monitoring using the Rotachrom Heparin reagent and Stago’s hybrid calibrator. Which control material should be used with this curve? Thanks! Hi, Crystal, I look forward […]

read more

Comments (0)

Anticoagulant Therapy

Sep 7 2012

george

Dabigatran Gene Variant

Here’s a new outcome from the Dabigatran etexilate RE-LY study that suggests there is a gene variant in 1/3 of Caucasians that converts less of the prodrug, reducing the risk of bleeding without reducing efficacy.

read more

Comments (0)

Anticoagulant Therapy

Aug 28 2012

george

PT/INR Results Using ISI 1.0 Reagents

From Terezinha Paz Munhoz: we started to use recombinant thromboplastin,RecombiPlasTin 2G (ISI 1.0) on our IL ACL TOP 500. The PT results are quite different from rabbit brain reagent. The high sensitivity shows a wide range: 8–220 seconds. We know the method linearity in this equipment is 8,0–320 seconds, and the percentage activity (that we still report) is “crazy” […]

read more

Comments (0)

Anticoagulant Therapy

Aug 25 2012

george

How Rapidly Does INR Decrease?

Here is a question that came to me from the American Society for Clinical Laboratory Science Consumer Web Forum: How quickly will an elevated international normalized ratio (INR, PT/INR) decrease/time? I appreciate the answer may be “it depends,” but for patients on warfarin and with an elevated INR (for example 4.0 in a patient with and INR […]

read more

Comments (0)

Anticoagulant Therapy

Aug 18 2012

george

Dabigatran Calibrators?

From Crystal Azevedo: I am currently evaluating the ECA-T kit to monitor dabigatran therapy. Are you aware of any labs/companies that have a set of validation plasmas? Sorry, Crystal, but no one is currently distributing dabigatran calibrators or controls, including the product developers at Diagnostica Stago, who have developed the research use only ecarin clotting assay (ECA) for […]

read more

Comments (1)

Anticoagulant Therapy

Aug 16 2012

george

A POC DTI Monitor

At the ASCLS/AACC meeting in July I had the opportunity to chat with Tonya Kiziah, MT (ASCP), Helena Laboratories, about Helena’s new hand-held Abrazo instrument, currently research use only, which offers a new point-of-care (POC) direct thrombin inhibitor (DTI) assay, DTM. DTM is a dry chemistry modification of the Ecarin clotting time that employs paramagnetic iron oxide particle technology, […]

read more

Comments (0)

Anticoagulant Therapy

Aug 16 2012

george

Establishing PTT Rx Range

From “Kkehoe“: Recognizing that the preferred method for establishing a partial thromboplastin time (PTT) therapeutic range for unfractionated heparin (UFH) is plotting the PTT against the anti-Xa, is there an alternative for labs that don’t perform anti-Xa testing? Are you aware of any commercial kits that can be purchased and used? We currently purchase a […]

read more

Comments (1)

Anticoagulant Therapy

Aug 2 2012

george

Monitoring Heparin with the Anti-Xa assay

From Crystal Azavedo: Hi George, Are you aware of any observation or randomized controlled trial data that compares bleeding and thrombosis risk in patients receiving unfractionated heparin monitored with the activated partial thromboplastin time (aPTT, PTT) compared to monitoring with anti-Xa? In other words, are there clinical outcome data that suggest monitoring with anti-Xa improves patient outcomes? Thanks!! […]

read more

Comments (0)

Anticoagulant Therapy